Biotech firms form "poison pills" to dodge takeover bids

03/9/2009 | Bloomberg

Small biotech companies are adopting "poison pill" strategies to prevent unsolicited buyout offers from big drugmakers. Avigen revised its stockholder-rights plan to include a measure that dilutes stock for any firm acquiring a 20% stake. CV Therapeutics' strategy limits investors from buying more than 15% of shares without the company's approval.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC